BioSpace News Archive

Genexine (KOSDAQ: 095700) today announced it received Fast Track Designation (FTD) from the Korean Ministry of Food and Drug Safety (MFDS) for GX-188E (tirvalimogene teraplasmid), its first-in-class proprietary therapeutic DNA vaccine.

ADARx Pharmaceuticals, Inc., a clinical stage biotechnology company developing RNA-targeting therapeutics, today announced the dosing of the first cohort in a Phase 1 clinical study of ADX-324 for the treatment of hereditary angioedema (HAE).

On the journey from gene to protein, a nascent RNA molecule can be cut and joined, or spliced, in different ways before being translated into a protein.

Quest Diagnostics Incorporated (NYSE: DGX), the world’s leading provider of diagnostic information services, announced that it will report fourth quarter and full year 2022 financial results on Thursday, February 2, 2023, before the market opens.

Cybeats Technologies Corp. (“Cybeats’’ or the “Company”) (CSE: CYBT) is pleased to announce a new software licence agreement with a top 3 global medical device and diagnostics leader, for Cybeats’ SBOM Studio1, to manage their Software Bill of Materials (SBOM) and support regulatory compliance requirements with looming FDA mandates on SBOM adoption for medical device manufacturers.

Avidity Biosciences, Inc. announced that on January 20, 2023, the Compensation Committee of Avidity’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 12,350 shares of its common stock and 6,175 restricted stock units to three new non-executive employees under the Avidity Biosciences, Inc.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, is taking part in a webinar hosted by Edison Group, which will focus on Volition’s Nu.Q® Vet commercial strategy.

Catalent, Inc. today announced that it will release financial results for the second quarter of fiscal year 2023 ended December 31, 2022, before the market open on Tuesday, February 7, 2023.

Able Medical Devices today announced the launch of Valkyrie® Looped Sternotomy Sutures.